ArticleJCO precision oncology2020
Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition.
Open access · bronzeAbstract read
In one paragraph
Article in JCO precision oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
99citing papers in PubMed, 3 pooled it
9.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed, 3 syntheses or guidelines pooled it, 135 citations in OpenAlex.
- BRAF-targeted therapy in non-melanomatous BRAF-mutant tumours: a systematic review of broad but histology-modulated efficacy.International journal of clinical oncology · 2026Pooled it
- Rebound regrowth phenomenon in patients with pediatric low-grade gliomas treated with MAPK inhibitors - a systematic review.Oncology reviews · 2026Pooled it
- The effects of dabrafenib and/or trametinib treatment in Braf V600-mutant glioma: a systematic review and meta-analysis.Neurosurgical review · 2024Pooled it
- Tumor-derived cell-free DNA detected in cerebrospinal fluid enables minimally invasive profiling of pediatric brain tumors.The Journal of clinical investigation · 2026Trial
- FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation-Positive Low-Grade Glioma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Efficacy and Safety of Trametinib Monotherapy or in Combination With Dabrafenib in PediatricJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma.Pediatric blood & cancer · 2021Trial
- Practical management of BRAF inhibitors in glioma: toxicity and resistance.CNS oncology · 2026Review
- Cytotoxic activity of selinexor in BRAFActa neuropathologica communications · 2026Article
- Efficacy Study of Vemurafenib in Children With Recurrent or Progressive BRAFJCO precision oncology · 2026Article
- Tempered optimism: Advances in the precision medicine era for pediatric low-grade glioma.Neuro-oncology · 2026Review
- Management of adverse events in patients with pediatric low-grade glioma treated with MAPK-directed therapies: Delphi consensus recommendations and unmet needs.Neuro-oncology practice · 2026Article
- RAS/MAPK inhibition in pediatric gliomas.Neuro-oncology advances · 2026Review
- Targeted therapies in adolescent and young adult patients with central nervous system tumors.Neuro-oncology advances · 2026Review
- The future of targeted therapies for pediatric central nervous system tumors.Neuro-oncology advances · 2026Review
- Pediatric Optic Pathway Gliomas: Diagnosis, Management, and Outcomes.International ophthalmology clinics · 2026Review
- Molecular convergence enables precision medicine for pediatric low grade gliomas.Discover oncology · 2026Review
- Integrated clinical and molecular landscape of disseminated pediatric low-grade glioma.Neuro-oncology · 2026Article
- A bibliometric analysis of progress and trends in pediatric glioma research.Discover oncology · 2026Article
- From Molecular Alterations to the Targeted Therapy: Treatment of Thalamic Glioma in Pediatric Patients.International journal of molecular sciences · 2026Review
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
73 authors at 20 institutions in 15 countries.
Liana NobreDepartment of Hematology and Oncology, Hospital for Sick Children, Toronto, ON, Canada.
Michal ZapotockyDepartment of Hematology and Oncology, Hospital for Sick Children, Toronto, ON, Canada.
Vijay RamaswamyDepartment of Hematology and Oncology, Hospital for Sick Children, Toronto, ON, Canada.
Scott RyallDepartment of Hematology and Oncology, Hospital for Sick Children, Toronto, ON, Canada.
Julie BennettDepartment of Hematology and Oncology, Hospital for Sick Children, Toronto, ON, Canada.
Daniel AldereteHospital of Pediatrics SAMIC Prof. Dr Juan P. Garrahan, Buenos Aires, Argentina.
Julia Balaguer GuillHospital Universitario y Politecnico La Fe, University of Valencia, Valencia, Spain.
Lorena BaroniHospital of Pediatrics SAMIC Prof. Dr Juan P. Garrahan, Buenos Aires, Argentina.
Ute BartelsDepartment of Hematology and Oncology, Hospital for Sick Children, Toronto, ON, Canada.
Abhishek BavleJimmy Everest Section of Pediatric Heamatology/Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK.
Miriam BornhorstChildren's National Health System, Washington, DC.
Daniel R BoueNationwide Children's Hospital and Ohio State University, Columbus, OH.
Adela CaneteHospital Universitario y Politecnico La Fe, University of Valencia, Valencia, Spain.
Murali ChintagumpalaTexas Children's Cancer Center, Houston, TX.
Scott L CovenDivision of Pediatric Hematology and Oncology, Department of Pediatrics, Indiana University, Indianapolis, IN.
Ofelia CruzHospital Sant Joan de Déu, Barcelona, Spain.
Sonika DahiyaWashington University School of Medicine, St Louis, MO.
Peter DirksArthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, ON, Canada.
Ira J DunkelMemorial Sloan Kettering Cancer Center, New York, NY.
David EisenstatStollery Children's Hospital, University of Alberta, Edmonton, AB, Canada.
Cecile Faure ConterInstitute d'Hémato-Oncologie Pédiatrique, Centre Leon Berard, Lyon, France.
Elizabeth FinchUniversity of North Carolina at Chapel Hill, Chapel Hill, NC.
Jonathan L FinlayNationwide Children's Hospital and Ohio State University, Columbus, OH.
Didier FrappazInstitute d'Hémato-Oncologie Pédiatrique, Centre Leon Berard, Lyon, France.
Maria Luisa GarreG. Gaslini Children's Hospital, Genoa, Italy.
Karen GauvainWashington University School of Medicine, St Louis, MO.
Anne Grete BechensteenOslo University Hospital, Oslo, Norway.
Jordan R HansfordRoyal Children's Hospital, Murdoch Children's Research Institute, University of Melbourne, Melbourne, VIC, Australia.
Inga HartingHopp Children's Cancer Center Heidelberg, Heidelberg, Germany.
Peter HauserSemmelweis University, Budapest, Hungary.
Lili-Naz HazratiDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Annie HuangDepartment of Hematology and Oncology, Hospital for Sick Children, Toronto, ON, Canada.
Sarah G InjacTexas Children's Cancer Center, Houston, TX.
Valentina IurilliG. Gaslini Children's Hospital, Genoa, Italy.
Matthias KarajannisMemorial Sloan Kettering Cancer Center, New York, NY.
Gurcharanjeet KaurMemorial Sloan Kettering Cancer Center, New York, NY.
Martin KynclSecond Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Lenka KrskovaSecond Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Normand LaperriereDepartment of Hematology and Oncology, Hospital for Sick Children, Toronto, ON, Canada.
Valerie LaroucheUniversite Laval, Quebec City, QC, Canada.
Alvaro LassalettaHospital Infantil Universitario Niño Jesús, Madrid, Spain.
Sarah LearySeattle Children's Hospital, Seattle, WA.
Frank LinTexas Children's Cancer Center, Houston, TX.
Samantha MascelliG. Gaslini Children's Hospital, Genoa, Italy.
Tara McKeownDepartment of Hematology and Oncology, Hospital for Sick Children, Toronto, ON, Canada.
Till MildeHopp Children's Cancer Center Heidelberg, Heidelberg, Germany.
Andres Morales La MadridHospital Sant Joan de Déu, Barcelona, Spain.
Giovanni MoranaG. Gaslini Children's Hospital, Genoa, Italy.
Helena MorseLund University, Lund, Sweden.
Naureen MushtaqAga Khan University Hospital, Karachi, Pakistan.
Diana S OsorioNationwide Children's Hospital and Ohio State University, Columbus, OH.
Roger PackerChildren's National Health System, Washington, DC.
Zdenek PavelkaUniversity Hospital Brno, Masaryk University, and ICRC Brno, Brno, Czech Republic.
Eduardo Quiroga-CanteroHospital Infantil Virgen del Rocío, Sevilla, Spain.
James RutkaArthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, ON, Canada.
Magnus SabelSahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden.
Duarte SalgadoPortuguese Oncology Institute, Lisbon, Portugal.
Palma SolanoHospital Infantil Virgen del Rocío, Sevilla, Spain.
Jaroslav SterbaUniversity Hospital Brno, Masaryk University, and ICRC Brno, Brno, Czech Republic.
Jack SuTexas Children's Cancer Center, Houston, TX.
David SumerauerSecond Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Michael D TaylorDevelopmental and Stem Cell Biology Program, Hospital for Sick Children, Toronto, ON, Canada.
Helen ToledanoSchneiders Children's Medical Center of Israel, Petah Tikva, Israel.
Derek S TsangDepartment of Hematology and Oncology, Hospital for Sick Children, Toronto, ON, Canada.
Mariana Valente FernandesPortuguese Oncology Institute, Lisbon, Portugal.
Frank van LandeghemStollery Children's Hospital, University of Alberta, Edmonton, AB, Canada.
Cornelis M van TilburgHopp Children's Cancer Center Heidelberg, Heidelberg, Germany.
Bev WilsonStollery Children's Hospital, University of Alberta, Edmonton, AB, Canada.
Olaf WittHopp Children's Cancer Center Heidelberg, Heidelberg, Germany.
Josef ZamecnikSecond Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
Eric BouffetDepartment of Hematology and Oncology, Hospital for Sick Children, Toronto, ON, Canada.
Cynthia HawkinsArthur and Sonia Labatt Brain Tumour Research Centre, Hospital for Sick Children, Toronto, ON, Canada.
Uri TaboriDepartment of Hematology and Oncology, Hospital for Sick Children, Toronto, ON, Canada.
Hospital for Sick Children · CAUniversity Hospital in Motol · CZChildren's Cancer Center · USHopp Children's Cancer Center Heidelberg · DEIstituto Giannina Gaslini · ITMemorial Sloan Kettering Cancer Center · USNationwide Children's Hospital · USUniversity of Toronto · CAChildren's National · USGarrahan Hospital · ARHospital Sant Joan de Déu Barcelona · ESHospital Universitario Virgen del Rocío · ESInstituto Português de Oncologia Francisco Gentil · PTStollery Children's Hospital · CAWashington University in St. Louis · USAga Khan University Hospital · PKCentre Léon Bérard · FRHospital Infantil Universitario Niño Jesús · ESHospital Universitari i Politècnic La Fe · ESIndiana University – Purdue University Indianapolis · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4MNCI NIH HHS P30 CA008748
Abstract
purposeChildren with pediatric gliomas harboring a BRAF V600E mutation have poor outcomes with current chemoradiotherapy strategies. Our aim was to study the role of targeted BRAF inhibition in these tumors. PATIENTS AND
methodsWe collected clinical, imaging, molecular, and outcome information from patients with BRAF V600E-mutated glioma treated with BRAF inhibition across 29 centers from multiple countries.
resultsSixty-seven patients were treated with BRAF inhibition (pediatric low-grade gliomas [PLGGs], n = 56; pediatric high-grade gliomas [PHGGs], n = 11) for up to 5.6 years. Objective responses were observed in 80% of PLGGs, compared with 28% observed with conventional chemotherapy (
conclusionUse of BRAF inhibition results in robust and durable responses in BRAF V600E-mutated PLGG. Prospective studies are required to determine long-term survival and functional outcomes with BRAF inhibitor therapy in childhood gliomas.
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.